Two Sigma Securities’s Bluejay Diagnostics BJDX Stock Holding History

Two Sigma Securities’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,588	Closed	-$9.6K	–	1682
2025 Q4	$9.6K	Buy	+3,588	New	+$23.6K	﹤0.01%	1296
2024 Q4	–	Sell	-263	Closed	-$6.68K	–	1775
2024 Q3	$6.68K	Buy	+263	New	+$18.8K	﹤0.01%	2651
2023 Q3	–	Sell	-1	Closed	-$7.12K	–	2944
2023 Q2	$7.12K	Buy	+1	New	+$9.04K	﹤0.01%	2634
2023 Q1	–	Sell	-1	Closed	-$6.78K	–	2668
2022 Q4	$6.78K	Buy	+1	New	+$21.7K	﹤0.01%	2419
2022 Q3	–	Sell	-1	Closed	-$23K	–	2613
2022 Q2	$23K	Buy	+1	New	+$35.5K	﹤0.01%	1937
2022 Q1	–	Hold	0	–	-$40K	–	2116
2021 Q4	–	Hold	0	–	–	–	1310

Other funds holding BJDX

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

L1 Global Manager Melbourne $142M AUM

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Two Sigma Securities's BJDX Position: Q1 2026 in Review

Two Sigma Securities sold out of Bluejay Diagnostics (BJDX) in Q1 2026, closing a stake of 3,588 shares — an estimated $9.6K sold.

Two Sigma Securities first reported a position in BJDX in Q2 2022 and held it in 5 quarters. The position peaked at $23K in Q2 2022. 6 funds tracked by Wall St. Rank hold BJDX as of Q1 2026.

Two Sigma Securities reported no remaining Bluejay Diagnostics position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 3,588 Bluejay Diagnostics shares in Q1 2026, an estimated $9.6K.
Two Sigma Securities first reported a position in Bluejay Diagnostics in Q2 2022 and held it in 5 quarters.
Two Sigma Securities's Bluejay Diagnostics position peaked at $23K in Q2 2022.
6 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.